Keywords: Celgene, Second-quarter 2011 financial results, Revlimid, Vidaza
Celgene 2nd-qtr 2011 boosted by Revlimid and Vidaza
Article | 01 August 2011
US biotech firm Celgene (NasdaqGS: CELG) has presented strong second-quarter 2011 results, with adjusted revenues climbed 38% to $1.18 billion, beating consensus estimates ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
